US regulators expand Mounjaro's label to include heart risk reduction for high-risk adults with type 2 diabetes

The US FDA has authorised Eli Lilly’s Mounjaro to be marketed for reducing major cardiovascular events in adults with type 2 diabetes at elevated risk, marking a significant milestone in incretin medicine approvals and cardiometabolic treatment strategies. US regulators have…













